Astellas Halts Gene Therapy Trial Following Serious Adverse Event
Astellas Pharma has stopped enrolling and dosing in a phase 1/2 clinical trial of its genetic therapy AT132 for X-linked myotubular myopathy, a rare neuromuscular disease, after a subject suffered a serious adverse event.
The Tokyo-based company said that a study participant had abnormal liver function test results weeks after receiving a low dose of AT132. Astellas said it has been communicating with regulatory agencies, which have not yet placed a clinical hold on the trial.
Of the 24 study participants, three had previously developed hepatitis and later died. The FDA imposed a clinical hold on the trial as a result, but lifted it in December 2020 after reviewing changes to the trial protocol.